Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ARAZLO - Health Canada Drug Approval Details

Approvals/Health Canada/ARAZLO

Authorized

STANDARD

ARAZLO

bausch health, canada inc.🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 6773ea5a6cce8db1
Company: bausch health, canada inc.
Type: Standard

Approval Details

Approval Id: 6773ea5a6cce8db1
Drug Approval Canada Name: ARAZLO
Product Name: ARAZLO
Status: Marketed
Status Date: 2021-09-16
Original Market Date: 2021-09-16
Din: 02517868
Drug Class: Human
Dosage Form: Lotion
Route Of Administration: Topical
Schedule: Prescription
Ahfs: 84:92.00
Atc Original: D05AX05 TAZAROTENE
Atc Name: d 05 ax 05
Aig Number: 0133047003
Company Name: bausch health, canada inc.
Company Address: 2150 Boul. St-Elzear Ouest, Laval, Quebec, Canada, H7L 4A8

Active Ingredients

TAZAROTENE

0.045 % / W/W

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

6773ea5a6cce8db1

Type

Standard

Back to Health Canada Approvals